To Assess the Correlation of High-resolution Specimen PET-CT Imaging, Using the XEOS AURA 10 PET-CT, With the Histopathology Results and Long-term Outcome of Patients Undergoing Resective Cancer Surgery.

Launched by XEOS MEDICAL · May 5, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at a new type of imaging called high-resolution specimen PET-CT, which uses a special device called the AURA 10 PET-CT. The goal is to see how well these images match up with results from the tissue samples taken during cancer surgery and how they might help doctors make better decisions for patients with prostate, breast, or head and neck cancers. By studying these connections, the researchers hope to improve how cancer is evaluated and treated, ultimately leading to better outcomes for patients.

To participate in the trial, individuals must be aged 18 or older and scheduled for surgery to remove cancer. They need to have high-resolution PET-CT imaging done on their removed tissue, which means the images should clearly show part of the tumor without any technical problems. Participants will be asked to give permission for their medical information to be used in the study. It's important to note that this trial is not yet recruiting participants, and pregnant or breastfeeding women are not eligible to join. Overall, this study aims to gather valuable information that could enhance cancer care in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria :
• • All patients that were scheduled for resective surgery and for whom successful high-resolution PET-CT imaging was performed on their resected specimens using the AURA 10 PET-CT. Successful imaging means that the image contains at least a portion of the primary tumor, the radiotracer injection was correctly executed and there were no technical issues that lead to an uninterpretable PET-CT image. Or all patients that are scheduled for resective surgery and for whom high-resolution PET-CT imaging will be performed on their resected specimens using the AURA 10 PET-CT.
• • Patients willing to provide informed consent for use of their relevant medical records. For retrospectively included patients with no further Long-Term Follow-Up (LTFU) data collection, a notification will be sent.
• Exclusion Criteria:
• • Under the age of 18 years at the time of resective surgery.
• • Women who are pregnant or breastfeeding.